4th Annual Midwest IBDHorizons Symposium
Access the live event at www.ibdhorizons.org/1149-2
It is a protected page! The password will be sent out in an email from Word Press to all registered attendees.
IBDHorizons Goes Virtual
Presenting the 4th Annual Midwest IBDH CME-accredited Symposium, now from the comfort of your own home.
This is a one-day virtual event to provide Continued Medical Education credit in underserved areas of IBD expertise. Where providers gather to discuss best practices in IBD management with a series of focused presentations, panel discussions, and case studies with dynamic attendee participation.
This event is free for attendees and meals will be provided through local delivery services for Breakfast, Lunch, and snacks.
Provided jointly by IBDHorizons and the Annenberg Center for Health Sciences at Eisenhower. This accredited education activity is supported by educational grants from AbbVie Inc., Bristol-Myers Squibb, Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Inc., and Takeda Pharmaceuticals U.S.A, Inc.
Topics
Approach to Management of Strictures: Resection, Stricturoplasty, Endoscopic or Medical Therapy?
Interpreting Negative Results from IBD Trials: What do they really mean?
Combining Current Therapies for Refractory CD: Ready for prime time?
Non-Invasive Disease Markers: Utility and Interpretation
Managing IBD Through a Pandemic: What lessons we learned through COVID-19
Decoding Arthropathy in IBD
The Crossover Between IBD and Irritable Bowel Syndrome
Telemedicine in IBD: Successes and Pitfalls
Target Audience
This activity was developed for providers caring for IBD patients including gastroenterologists, surgeons, gastroenterology nurses, advanced nurse practitioners, physician assistants, and pharmacists.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Describe the clinical presentation of Crohn’s disease patients with strictures and discuss the best management for strictures including surgical intervention, endoscopic management, and medical treatments.
- Appraise and interpret the negative results of a clinical trial where the primary clinical trial endpoint was not met, therefore FDA approval was not granted, and describe the implication these results have on clinical practice.
- Recognize the limitations of the available therapies to secure remission for the majority of IBD patients and analyze the current knowledge on combining different biologic and small molecule therapies regarding efficacy and risks in those patients not in remission.
- Identify available non-invasive testing to evaluate for disease activity in IBD and interpret these studies relative to other objective markers of disease such as endoscopy.
- Assess our current knowledge regarding COVID-19 and its implications on managing IBD patients during the current pandemic, including risk stratification for severe disease, risk of continuing or stopping IBD medications, and upcoming practice guidelines.
- Identify arthropathies associated with IBD and discern the etiology of the arthropathy which may be due to IBD, current medication, or other causes.
- Recognize the overlap between IBD and IBS and learn to approach active symptoms in a patient with IBD to better differentiate IBD from IBS and develop an appropriate treatment plan.
- Appraise the available telemedicine models of health care delivery with their advantages and limitations and apply this knowledge to enhance IBD patient care access and outcomes.
Accreditation and Certification
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity is co-provided by the Annenberg Center for Health Sciences at Eisenhower and the IBDHorizons.
Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 6.0 contact hours may be earned for successful completion of this activity.
Pharmacists
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity has been assigned ACPE Universal Program # 0797-9999-21-018-L01-P. This activity is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy education credit. This is a knowledge-based activity.
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited educational activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, disclosure information will be provided at the beginning of the activity.
Date
Time
ESTSpeakers
-
Alan Moss, MDAssociate Professor of Medicine, Gastroenterology at Boston University School of Medicine
Dr. Alan Moss, MD, FACG, AGAF, FEBG, FRCPI is a clinician-scientist with an interest in Inflammatory Bowel Disease (IBD). His clinical expertise is in the management of IBD, and he is Director of the Crohn’s & Colitis Program at Boston Medical Center. His research interests include microbial therapeutics, mucosal immunology, and clinical outcomes. He has held grant funding from NIDDK, AGA, Helmsley Charitable Trust, and the Crohn’s & Colitis Foundation (CCF). He has published over 120 research papers (h-index 28), including many cited in national and international practice guidelines. Dr. Moss has held positions as Deputy-Editor of Crohn’s & Colitis 360, and as Associate Editor for Journal of Crohn’s & Colitis (ECCO), Frontline Gastroenterology (BMJ), and the World Journal of Gastroenterology. He has served on the Nominating Committee of the IBD section of AGA, and the Professional Education and National Scientific Advisory Committee for the Crohn’s & Colitis Foundation. He is a reviewer for national and international research bodies, including the NIDDK and European Research Council.
-
Aline Charabaty, MDClinical Director of Gastroenterology, Sibley Memorial Hospital and Director of the Inflammatory Bowel Disease Center at Sibley Memorial Hospital, Assistant Professor of Medicine
Dr. Aline Charabaty is the Director of the Inflammatory Bowel Diseases (IBD) Center at Sibley Memorial Hospital.
She received her medical degree from Saint Joseph University School of Medicine, Beirut, and completed her internal medicine residency and gastroenterology fellowship at MedStar Georgetown University Hospital. Before joining Johns Hopkins Medicine, Dr. Charabaty was the director of the IBD Center at MedStar Georgetown University Hospital for more than 10 years.
In addition to her expertise in IBD, Dr. Charabaty has a particular interest in women’s health, celiac disease, and cancer prevention.
Dr. Charabaty has consulted for the FDA and she is the chair of the Crohn’s and Colitis Foundation of the D.C. metropolitan area. She is a reviewer for peer-reviewed gastroenterology journals and section editor for Practical Reviews in Gastroenterology.
Dr. Charabaty received the Gastroenterology Award in Excellence in Teaching Residents and Fellows from Georgetown University and has also been recognized as “Top Doctor” by her peers in Washingtonian Magazine and the Washington Consumers’ CheckBook.
-
Anita Afzali, MD, MPH, MHCMProfessor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
-
Brian Feagan, MD, MScProfessor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Inflammatory Bowel Diseases (IBD), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in IBD. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology (ACG), the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored numerous articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
-
Feza Remzi, MDVice President and Colorectal Surgeon at Northwell Health Center for Advanced IBD Care, New York
Dr. Feza Remzi is the Vice President and a colorectal surgeon at the Center for Advanced IBD Care at Northwell Health in New York.
He is a national and international expert in colorectal surgery, specializing in the surgical management of inflammatory bowel disease (IBD). He performs pelvic pouch surgery, complex abdominopelvic re-operative surgery, and sphincter-saving surgery for rectal cancer, utilizing minimally invasive techniques to manage colorectal conditions.
Dr. Remzi resides in New York with his wife and son. They enjoy traveling and spending time together as a family.
Dr. Remzi is an Honorary IBDHorizons Board member.
@FezaRemziMD
-
Ghassan Wahbeh, MDDirector of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children’s.
Dr. Wahbeh’s research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children’s Hospital.
Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.
He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
-
Stephen B. Hanauer, MDProfessor of Medicine, Clinical Pharmacology, Chief of the Section of Gastroenterology and Nutrition
Stephen B. Hanauer received his bachelor’s degree from the University of Michigan in Ann Arbor, Michigan, and his medical degree, with honors, from the University of Illinois in Chicago, IL. He completed his internship and residency in internal medicine, as well as his fellowship in gastroenterology, at the University of Chicago, where he is currently the Joseph B. Kirsner Professor of Medicine and Clinical Pharmacology, and Chief of the Section of Gastroenterology and Nutrition at the University of Chicago. Is the author or co-author of hundreds of peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. He also designed and maintains a 6000-patient database for the Inflammatory Bowel Disease Registry. He is incoming IBD Section editor for Clinical Gastroenterology and Hepatology, and former Editor-in-Chief of Nature Clinical Practice Gastroenterology and Hepatology, and serves on the editorial boards of numerous other medical journals, including the American Journal of Gastroenterology (AJG), and Inflammatory Bowel Diseases. Is the past chair of the Immunology, Microbiology, and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA). He is also a recipient of the AGA’s Fiterman Award for Clinical Research, and the AGA’s Janssen Award for Clinical Excellence. Additionally, he has been named one of America’s Top Doctors by Castle Connolly Medical Ltd. Has previously served as a member and Chair of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee. He currently serves as Chair of the International Organization for Inflammatory Bowel Disease, Secretary-Elect of the American College of Gastroenterology (ACG), and a member of the GI Specialty Board of Internal Medicine.
Hourly Schedule
Morning Session: Afzali Moderating
- 8:00AM - 8:15AM
- Welcome & Introduction
- 8:15AM - 9:00AM
- Non-invasive Disease Markers: Utility and Interpretation
-
Speakers:
Ghassan Wahbeh-- MD
- 9:00AM - 9:45AM
- Interpreting Negative Results from IBD Trials: What Do They Really Mean?
-
Speakers:
Brian Feagan-- MD-- MSc
- 9:45AM - 10:15AM
- Break
- 11:00AM - 11:45AM
- Approach to Management of Strictures: Resection, Stricturoplasty, Endoscopic or Medical Therapy?
-
Speakers:
Feza Remzi-- MD
- 11:45AM - 12:30PM
- Lunch
Afternoon Session: Afzali Moderating
- 12:30PM - 1:15PM
- Managing IBD Through a Pandemic: What Lessons We Learned Through COVID-19
-
Speakers:
Stephen B. Hanauer-- MD
- 1:15PM - 2:00PM
- Decoding Arthropathy in IBD
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- 2:00PM - 2:45PM
- The Crossover Between IBD & Irritable Bowel Syndrome
- Panel Discussion
-
Speakers:
Aline Charabaty-- MD
- 2:45PM - 3:00PM
- Telemedicine in IBD: Successes and Pitfalls
-
Speakers:
Alan Moss-- MD
- 3:00PM - 3:30PM
- Take Home Message Review
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM